Johnson & Johnson and its subsidiary Janssen Pharmaceuticals were blamed as plaintiff Nicholas Murray told the Philadelphia court that the drug Risperdal, prescribed to treat schizophrenia and bipolar disorder, had made him grow breasts.
Pennsylvania jury decided Tuesday that US pharmaceutical giant Johnson & Johnson must pay $ 8 billion in damages and interest for failing to warn that psychiatric drugs can cause breast growth in men.
Johnson & Johnson and its subsidiary Janssen Pharmaceuticals blamed as the plaintiff Nicholas Murray told the court that the drug Risperdal Philadelphia, prescribed to treat schizophrenia and bipolar disorder, has made him grow breasts.
Challenging the company’s decision in a statement, calling the damage given “disproportionate” with an initial award of $ 680,000 in the case.
“The company believes (the decision) will be reversed,” the statement said, and “will soon be moving to set aside the verdict excessive and baseless.”
In the statement, Johnson & Johnson accused the courts to prevent them from presenting the defense team “key evidence” on the label Risperdal.
The company is facing a series of complaints in state court for failing to properly warn of side effects of Risperdal, including in Pennsylvania, California, and Missouri.
Risperdal is approved for the treatment of adults by the US Food and Drug Administration in 1993, bringing some $ 737 million (672 million euros) in sales in 2018.
To advertise with Brampton-News, please contact our advertising team here: Advertise with us.